Follicular Lymphoma Market is expected to Reach USD 3,081 million in 2034

The Follicular Lymphoma market across the seven major markets (7MM: US, EU4, UK, and Japan) is projected to expand from USD 1,702 million in 2025 to USD 3,081 million by 2034, reflecting a compound annual growth rate (CAGR) of 6.8%.

Follicular lymphoma, an indolent form of non-Hodgkin lymphoma derived from germinal center B cells, remains one of the most common subtypes of slow‑progressing B‑cell lymphomas. Although incurable in most cases, its chronic nature allows for long‑term disease management. Diagnosis primarily relies on morphological evaluation of excised lymph node tissue, showcasing mixed cellular patterns of small cleaved (centrocyte) and large noncleaved (centroblast) B cells.

In 2024, approximately 35,000 cases were diagnosed across the 7MM, with women accounting for about 18,000 cases. The United States leads the Follicular Lymphoma market, valued at around USD 1,000 million, due to higher diagnosis rates and the early adoption of advanced therapies.

Approved treatments currently addressing Follicular Lymphoma include GAZYVA, TAZVERIK, EPKINLY (TEPKINLY), LUNSUMIO, YESCARTA, BREYANZI, KYMRIAH, BRUKINSA, ORDSPONO, and RITUXAN HYCELA. Additionally, several promising new therapies are in development, such as MONJUVI (tafasitamab), AZD0486, Golcadomide, Abexinostat, NKTR‑255, CTX112, and IMPT‑314, which are expected to further expand therapeutic options between 2024 and 2034.

Among notable regulatory updates, Regeneron Pharmaceuticals resubmitted its Biologics License Application (BLA) for odronextamab to the FDA in February 2025 for relapsed or refractory follicular lymphoma, with a decision anticipated in the second half of 2025.

Overall, the Follicular Lymphoma market outlook remains robust, supported by ongoing clinical advancements, expanding therapeutic pipelines, and increasing disease awareness across global markets. The United States is expected to maintain its position as the largest contributor to market revenue throughout the forecast period.

DelveInsight has released its latest report, “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034,” offering an in-depth analysis of the evolving dynamics, treatment landscape, and commercial outlook of the global Follicular Lymphoma (FL) market. The study forecasts the market to grow at a CAGR of 6% during 2025–2034, propelled by expanding treatment awareness, advances in immuno-oncology, and a robust pipeline of emerging therapies.

The report covers the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan - with a focus on epidemiology trends, regulatory approvals, and competitive insights from leading pharmaceutical developers.

Follicular Lymphoma Rising Prevalence and Market Growth Outlook

In 2024, the global Follicular Lymphoma market was valued at approximately USD 1,082 million across the 7MM and is anticipated to achieve sustained growth through 2034. Increased disease awareness has led to earlier detection and higher treatment rates, directly contributing to expanding market size.

The United States represented the largest market segment with nearly USD 1 billion of revenue in 2024, followed by Germany, valued at around USD 108 million. Spain represented the smallest share among EU markets with an estimated value of USD 61 million.

Across the 7MM, approximately 35,000 new cases of Follicular Lymphoma were diagnosed in 2024. The U.S. accounted for nearly half of these, with around 17,000 cases. The majority of patients (about 9,000) were aged between 60 and 80, while stage IV FL represented about one-third of total diagnoses.

Key Follicular Lymphoma Clinical Trial Advances and Regulatory Updates

Recent years have seen accelerated clinical development and regulatory milestones in the Follicular Lymphoma treatment landscape:

• Regeneron Pharmaceuticals (February 2025): Resubmitted the Biologics License Application (BLA) for odronextamab for relapsed or refractory FL, with an FDA decision expected by late 2025.
• Genmab A/S (February 2025): Received approval from Japan’s Ministry of Health, Labour, and Welfare for EPKINLY (epcoritamab) in relapsed or refractory FL (Grades 1–3A), marking the first subcutaneous T-cell engaging bispecific antibody of its kind approved in Japan.
• CRISPR Therapeutics (January 2025): Announced collaboration with regulatory agencies to advance CTX112 in B-cell malignancies, with an update expected mid-2025.
• FDA (September 2024): Granted Priority Review for odronextamab targeting adults with relapsed or refractory FL and diffuse large B-cell lymphoma (DLBCL).

These developments underscore a growing regulatory emphasis on novel immunotherapies, biomarker-driven treatment strategies, and patient-centric drug formulations.

Follicular Lymphoma Overview

Follicular Lymphoma is a slow-growing subtype of non-Hodgkin lymphoma originating from B-lymphocytes. It typically occurs in the lymph nodes and may spread to the bone marrow or spleen. Characterized by abnormal follicle formation, the disease often presents with painless swelling of lymph nodes, fatigue, and systemic B-symptoms such as night sweats and weight loss.

Diagnosis involves physical examination, imaging, biopsy, and molecular testing to confirm hallmark mutations-especially BCL2 rearrangements. While incurable, FL remains highly manageable, and emerging targeted therapies are significantly improving progression-free survival and patient quality of life.

Follicular Lymphoma Treatment Landscape and Emerging Therapies

Treatment strategies depend on disease stage and symptoms. Early-stage cases may be monitored through active surveillance, while advanced cases typically require immunotherapy, chemotherapy, radiotherapy, or targeted biologics.

DelveInsight highlights several key marketed and pipeline therapies expected to reshape future treatment standards:

• LUNSUMIO (mosunetuzumab) – Roche
• BRUKINSA (zanubrutinib) – BeiGene
• YESCARTA – Kite Pharma
• MONJUVI (tafasitamab) – Incyte Corporation
• AZD0486 – AstraZeneca
• Tisagenlecleucel – Novartis
• Odronextamab – Regeneron
• Tazemetostat – Epizyme Inc.
• Rituximab IV – Roche
• Atezolizumab (TECENTRIQ) – Hoffmann-La Roche
• Loncastuximab tesirine – ADC Therapeutics S.A
• Ibrutinib – AbbVie / Pharmacyclics
• IXAZOMIB – Millennium Pharma

The advancement of bispecific antibodies, CAR-T therapies, and small-molecule inhibitors has transformed the treatment paradigm for FL. Drugs like mosunetuzumab and epcoritamab are demonstrating promising efficacy even in relapsed or refractory settings.

Follicular Lymphoma Epidemiology Insights

The report provides a detailed analysis of Follicular Lymphoma epidemiology across the 7MM, with segmentation by severity, age, gender, and stage. Key highlights include:

• Total prevalence and incidence dynamics through 2034
• Country-specific patient distribution
• Diagnosed episodic versus chronic cases
• Trends in age-related prevalence (notably among patients 60+)

DelveInsight’s epidemiological projection reveals a consistent increase in both incidence and diagnosis rates, reinforcing the importance of improved access to care and early-stage detection initiatives.

Follicular Lymphoma Market Dynamics: Drivers, Barriers, and Unmet Needs

Follicular Lymphoma Market Drivers:

• Rising awareness and screening initiatives leading to early detection
• Expanding availability of next-generation targeted drugs
• High research collaboration between academic centers and industry
• Favorable reimbursement policies in key markets

Follicular Lymphoma Market Barriers:

• High cost of advanced therapeutic agents
• Limited access in developing healthcare systems
• Adverse effects and safety concerns associated with long-term immunotherapies

Current unmet needs remain in the areas of durable remission, cost-effective targeted therapies, and simplified administration routes that maintain patient adherence and quality of life.

Follicular Lymphoma Competitive Landscape and Company Analysis

Prominent players in the global Follicular Lymphoma market include: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Eli Lilly and Company, ADC Therapeutics, Cephalon, Epizyme, Pharmacyclics, AbbVie, Millennium Pharma, Gemin X, and Xynomic Pharmaceuticals.

DelveInsight’s report also includes detailed competitive intelligence analysis - encompassing SWOT analysis, PESTLE evaluation, Porter's Five Forces framework, BCG matrix, and market entry strategies - to provide investors and stakeholders with actionable insights into future growth opportunities.

Follicular Lymphoma Market Forecast and Outlook

DelveInsight projects that the U.S. Follicular Lymphoma market will expand exponentially through 2034, fueled by rapid adoption of monoclonal antibodies, bispecifics, and CAR-T therapies. The aging population, especially in Western markets, continues to be a critical factor influencing prevalence and treatment volumes.

Emerging therapies are expected to redefine care standards and boost market share for innovative manufacturers. The ongoing introduction of advanced pipeline products will likely deliver transformative outcomes and drive robust commercial growth across all seven major markets.

Scope of the Report

• Study Period: 2020–2034
• Geographic Coverage: United States, EU5 (Germany, France, Italy, Spain, United Kingdom), and Japan
• Current and emerging therapy analysis
• Market drivers and restraints
• Unmet medical needs and future opportunities
• Epidemiological modeling and forecast trends
• Comprehensive reimbursement and access evaluation